Jazz Commits Up to $4B for T Cell Engagers with AbCellera

Strategic News Watch — June 17, 2026

Jazz Pharmaceuticals committed up to $4 billion to an AbCellera collaboration on next-generation T cell engagers for solid tumors — while two hacking groups hit Novo Nordisk with multi-million-dollar ransom demands and Bristol Myers Squibb posted positive Phase III multiple myeloma data at EHA26.

Today’s top developments:

Jazz Pharmaceuticals will pay up to $4 billion to collaborate with AbCellera on multispecific T cell engagers beyond hematologic malignancies (BioPharma Dive)
Two separate hacking groups obtained sensitive Novo Nordisk data and allegedly attempted to extort multi-million-dollar ransoms (Fierce Pharma)
A prominent venture capitalist publicly opposed proposed U.S. restrictions on biotech investments that could benefit China’s drug industry (STAT)
Bristol Myers Squibb reported positive Phase III mezigdomide and Phase I CAR-T multiple myeloma data at EHA26 (Pharmaceutical Technology)
AviadoBio expanded its exclusive King’s College London license for the vMiX RNAi gene-silencing platform across all human therapeutic areas (Pharmaceutical Technology)
Altaris agreed to acquire model-based drug development software provider Simulations Plus for $375 million in an all-cash transaction (Pharmaceutical Technology)
InStride closed a $30 million Series C led by Echo Health Ventures and FMZ Ventures to scale its pediatric mental health platform (MedCity News)

What to Watch

T Cell Engager Expansion: Jazz-AbCellera’s $4B collaboration targeting solid tumors will test whether next-generation engineering can overcome microenvironment barriers that limited first-gen bispecifics to hematologic malignancies.
Pharma Cybersecurity Vulnerabilities: Novo’s dual ransomware attacks may prompt sector-wide security audits and signal escalating threats to companies with high-value IP and supply chain criticality.
China Investment Restrictions: Proposed federal limitations on U.S.-China biotech deals could reshape global clinical development strategies and force portfolio companies to choose jurisdictional allegiances.
Pharma Software Consolidation: Altaris’s $375M Simulations Plus acquisition signals continued PE interest in model-based drug development tooling; watch for follow-on roll-ups across fragmented modeling, simulation, and PK/PD software vendors as sponsors push for integrated platforms.

This brief highlights the edition’s top stories. Read the latest edition → for all stories and analysis.

Related Stories

Sino Biopharm Strikes Drug Licensing Deal With AstraZeneca, Deepens Partnership With GSK

Novartis Pays $1.1B Upfront for Myricx Bio ADC Platform

Vera’s TRUTAKNA Wins FDA Accelerated Approval for IgA Nephropathy

You May Have Missed

FDA Warning Letter Hits Sanofi’s Genzyme Ireland Site

Sino Biopharm Strikes Drug Licensing Deal With AstraZeneca, Deepens Partnership With GSK

Novartis Pays $1.1B Upfront for Myricx Bio ADC Platform

Vera’s TRUTAKNA Wins FDA Accelerated Approval for IgA Nephropathy